Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Molecular size distributions of apolipoprotein E and alpha-synuclein in post mortem cerebrospinal fluid and brain tissues from Alzheimer’s and Parkinson’s disease patients with an APOEε3/ε4 genotype
Stockholm University, Faculty of Science, Department of Biochemistry and Biophysics. (Dr. Henrietta M. Nielsen)ORCID iD: 0000-0002-3649-1281
Stockholm University, Faculty of Science, Department of Biochemistry and Biophysics. (Dr. Henrietta M. Nielsen)
Stockholm University, Faculty of Science, Department of Biochemistry and Biophysics. (Dr. Henrietta M. Nielsen)
Stockholm University, Faculty of Science, Department of Biochemistry and Biophysics. (Dr. Henrietta M. Nielsen)
(English)Manuscript (preprint) (Other academic)
Abstract [en]

The apolipoprotein E epsilon 4 allele (APOEε4) is the strongest genetic risk factor for both sporadic Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB). Carriers of APOEε4 have more abundant AD amyloid-β pathology, and recent findings further suggest that the allele promotes α‑synuclein (αSyn) pathology. We have previously described an APOEε4 dose-depended increase in cerebrospinal fluid (CSF) αSyn levels in prodromal AD patients and elevated levels of monomeric intracellular αSyn were reported in AD brains lacking Lewy pathology. Importantly, over 50% of sporadic AD patients exhibit notable levels of Lewy pathology and a majority of PSEN1 mutation-carrying familial AD patients exhibit αSyn pathology in the amygdala. Here we assessed the levels and molecular size distribution of αSyn, total apolipoprotein E (apoE), and apoE4 in ventricular CSF from APOEε3/ε4-carrying patients with AD and Parkinson’s disease (PD), and controls using size exclusion chromatography, ELISA and western blotting. We further assessed brain regional differences in the solubilities and molecular species of αSyn and apoE and apoE4 using tissue fractionation and western blotting. Levels of CSF apoE and apoE4 were lower in AD versus PD patients, while levels of CSF αSyn were generally higher than reported in ante mortem lumbar CSF samples. No notable co-elution of αSyn and apoE occurred in CSF. In the brain parenchyma, compared to the medial frontal gyrus and medial temporal gyrus, the amygdala had higher levels and more species of saline and Triton X‑100 soluble apoE4 and αSyn regardless of patient diagnosis. Overall, our results suggest that levels of postmortem CSF apoE and apoE4 are reduced in AD versus PD patients, and that the amygdala appears to have a unique, but not a disease-specific pattern of apoE4 and αSyn molecular species.

Keywords [en]
apoE, α-synuclein, Alzheimer’s disease, Parkinson’s disease, post mortem, cerebrospinal fluid, brain tissue, molecular size
National Category
Neurosciences
Research subject
Neurochemistry with Molecular Neurobiology
Identifiers
URN: urn:nbn:se:su:diva-197745OAI: oai:DiVA.org:su-197745DiVA, id: diva2:1602878
Available from: 2021-10-13 Created: 2021-10-13 Last updated: 2022-02-25Bibliographically approved
In thesis
1. Apolipoprotein E and alpha-synuclein interactions, and their associations with neurodegenerative diseases
Open this publication in new window or tab >>Apolipoprotein E and alpha-synuclein interactions, and their associations with neurodegenerative diseases
2021 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

The apolipoprotein E gene (APOE) is expressed as three major isoforms, APOE ε2, ε3 and ε4 that encode the apoE2, E3 and E4 proteins, respectively. APOE ε4 is associated with an increased risk for age-related neurodegenerative diseases including Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), and increases the risk of dementia in Parkinson’s disease (PD), however, the exact molecular mechanisms underpinning the associations between APOE ε4 and neurodegeneration are still unknown. Pathologically, α-synuclein (αSyn) is the primary component of Lewy neuropathology which is stereotypically found in PD, DLB and also in the majority of AD brains upon post mortem examination, and changes in the soluble levels of intra- and extracellular αSyn in the central nervous system have been found in AD patients compared to cognitively healthy individuals. With this in mind, we hypothesized that interactions, both direct and indirect, between apoE4 / APOE ε4 and αSyn might help explain their associations with the pathogenesis of multiple neurodegenerative diseases. Using mouse models with a humanized APOE ε4/ε4 or ε3/ε3 liver genotype we found that changing the liver genotype to APOE ε4/ε4 led to a re-compartmentalization of brain αSyn and significant changes in key pre- and postsynaptic protein levels We also found that in prodromal sporadic AD patients APOE ε4 carriers had significantly increased cerebrospinal fluid (CSF) αSyn levels, and in autosomal dominant AD APOE ε4 carriers higher CSF αSyn levels that were correlated with AD-onset and increasing brain amyloid-β plaque deposition. When next assessing any disease related changes in the molecular sizes of αSyn and apoE in AD and PD post mortem brain parenchyma we found that the amygdala had a differing distribution of αSyn and apoE4 species. Co-incubation of the recombinant apoE isoforms and αSyn led to high molecular weight αSyn species, increased high molecular weight apoE2 species and a stabilized pool of monomeric apoE3. Using, binding kinetics assays and human neuronal cell cultures we found that recombinant apoE isoforms bind with similar strength to αSyn and reduce αSyn cellular uptake, whereas astrocyte secreted apoE led to an apoE- isoform-dependent reduction in αSyn uptake (apoE4 > apoE3 > apoE2). Further, heparin sulfate proteoglycans were partially responsible for αSyn uptake mediated by apoE. Taken together, our results show that APOE / apoE is linked to changes in levels, species and compartmentalization of αSyn in multiple pathological contexts ranging from the central nervus system to the periphery in humans, mouse models and cell lines. Our data reinforce the growing body of literature linking APOE / apoE and αSyn to the pathogenesis of the most prevalent neurodegenerative diseases.

Place, publisher, year, edition, pages
Stockholm: Department of Biochemistry and Biophysics, Stockholm University, 2021. p. 99
National Category
Neurosciences
Research subject
Neurochemistry with Molecular Neurobiology
Identifiers
urn:nbn:se:su:diva-197746 (URN)978-91-7911-652-1 (ISBN)978-91-7911-653-8 (ISBN)
Public defence
2021-11-23, Magnélisalen, Kemiska övningslaboratoriet, Svante Arrhenius väg 16 B, Stockholm, 14:00 (English)
Opponent
Supervisors
Available from: 2021-10-29 Created: 2021-10-13 Last updated: 2022-02-25Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records

Twohig, DanielEdlund, AnnaNielsen, Henrietta

Search in DiVA

By author/editor
Twohig, DanielEdlund, AnnaNielsen, Henrietta
By organisation
Department of Biochemistry and Biophysics
Neurosciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 173 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf